Development and pilot-testing of the Alopecia Areata Assessment Tool (ALTO).

BACKGROUND:Alopecia areata (AA) is an autoimmune disease characterized by non-scarring hair loss. The lack of a definitive biomarker or formal diagnostic criteria for AA limits our ability to define the epidemiology of the disease. In this study, we developed and tested the Alopecia Areata Assessmen...

Full description

Bibliographic Details
Main Authors: David G Li, Kathie P Huang, Fan Di Xia, Cara Joyce, Deborah A Scott, Abrar A Qureshi, Arash Mostaghimi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5991373?pdf=render
id doaj-ed83beca29b04b64b59adcd5a14c4e52
record_format Article
spelling doaj-ed83beca29b04b64b59adcd5a14c4e522020-11-25T00:04:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01136e019651710.1371/journal.pone.0196517Development and pilot-testing of the Alopecia Areata Assessment Tool (ALTO).David G LiKathie P HuangFan Di XiaCara JoyceDeborah A ScottAbrar A QureshiArash MostaghimiBACKGROUND:Alopecia areata (AA) is an autoimmune disease characterized by non-scarring hair loss. The lack of a definitive biomarker or formal diagnostic criteria for AA limits our ability to define the epidemiology of the disease. In this study, we developed and tested the Alopecia Areata Assessment Tool (ALTO) in an academic medical center to validate the ability of this questionnaire in identifying AA cases. METHODS:The ALTO is a novel, self-administered questionnaire consisting of 8 closed-ended questions derived by the Delphi method. This prospective pilot study was administered during a 1-year period in outpatient dermatology clinics. Eligible patients (18 years or older with chief concern of hair loss) were recruited consecutively. No patients declined to participate. The patient's hair loss diagnosis was determined by a board-certified dermatologist. Nine scoring algorithms were created and used to evaluate the accuracy of the ALTO in identifying AA. RESULTS:239 patients (59 AA cases and 180 non-AA cases) completed the ALTO and were included for analysis. Algorithm 5 demonstrated the highest sensitivity (89.8%) while algorithm 3 demonstrated the highest specificity (97.8%). Select questions were also effective in clarifying disease phenotype. CONCLUSION:In this study. we have successfully demonstrated that ALTO is a simple tool capable of discriminating AA from other types of hair loss. The ALTO may be useful to identify individuals with AA within large populations.http://europepmc.org/articles/PMC5991373?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author David G Li
Kathie P Huang
Fan Di Xia
Cara Joyce
Deborah A Scott
Abrar A Qureshi
Arash Mostaghimi
spellingShingle David G Li
Kathie P Huang
Fan Di Xia
Cara Joyce
Deborah A Scott
Abrar A Qureshi
Arash Mostaghimi
Development and pilot-testing of the Alopecia Areata Assessment Tool (ALTO).
PLoS ONE
author_facet David G Li
Kathie P Huang
Fan Di Xia
Cara Joyce
Deborah A Scott
Abrar A Qureshi
Arash Mostaghimi
author_sort David G Li
title Development and pilot-testing of the Alopecia Areata Assessment Tool (ALTO).
title_short Development and pilot-testing of the Alopecia Areata Assessment Tool (ALTO).
title_full Development and pilot-testing of the Alopecia Areata Assessment Tool (ALTO).
title_fullStr Development and pilot-testing of the Alopecia Areata Assessment Tool (ALTO).
title_full_unstemmed Development and pilot-testing of the Alopecia Areata Assessment Tool (ALTO).
title_sort development and pilot-testing of the alopecia areata assessment tool (alto).
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2018-01-01
description BACKGROUND:Alopecia areata (AA) is an autoimmune disease characterized by non-scarring hair loss. The lack of a definitive biomarker or formal diagnostic criteria for AA limits our ability to define the epidemiology of the disease. In this study, we developed and tested the Alopecia Areata Assessment Tool (ALTO) in an academic medical center to validate the ability of this questionnaire in identifying AA cases. METHODS:The ALTO is a novel, self-administered questionnaire consisting of 8 closed-ended questions derived by the Delphi method. This prospective pilot study was administered during a 1-year period in outpatient dermatology clinics. Eligible patients (18 years or older with chief concern of hair loss) were recruited consecutively. No patients declined to participate. The patient's hair loss diagnosis was determined by a board-certified dermatologist. Nine scoring algorithms were created and used to evaluate the accuracy of the ALTO in identifying AA. RESULTS:239 patients (59 AA cases and 180 non-AA cases) completed the ALTO and were included for analysis. Algorithm 5 demonstrated the highest sensitivity (89.8%) while algorithm 3 demonstrated the highest specificity (97.8%). Select questions were also effective in clarifying disease phenotype. CONCLUSION:In this study. we have successfully demonstrated that ALTO is a simple tool capable of discriminating AA from other types of hair loss. The ALTO may be useful to identify individuals with AA within large populations.
url http://europepmc.org/articles/PMC5991373?pdf=render
work_keys_str_mv AT davidgli developmentandpilottestingofthealopeciaareataassessmenttoolalto
AT kathiephuang developmentandpilottestingofthealopeciaareataassessmenttoolalto
AT fandixia developmentandpilottestingofthealopeciaareataassessmenttoolalto
AT carajoyce developmentandpilottestingofthealopeciaareataassessmenttoolalto
AT deborahascott developmentandpilottestingofthealopeciaareataassessmenttoolalto
AT abraraqureshi developmentandpilottestingofthealopeciaareataassessmenttoolalto
AT arashmostaghimi developmentandpilottestingofthealopeciaareataassessmenttoolalto
_version_ 1725429122149122048